New hope for transplant patients when standard treatment fails
NCT ID NCT07484113
Summary
This early-stage study is testing whether adding the drug sarilumab helps adults with chronic graft-versus-host disease (cGVHD) when their current treatment (belumosudil) isn't working well. Researchers will check if the combination is safe and shows any signs of helping control the disease. The trial involves 10 participants at Stanford University who have cGVHD that continues despite taking belumosudil.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGVHD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.